A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.
about
Measuring melasma patients' quality of life using willingness to pay and time trade-off methods in Thai population.Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infantsAssessing quality of life in older adult patients with skin disorders.Patient preference quality of life measures in dermatology.Does cost-effectiveness play a role in clinical trials?Pimecrolimus versus topical corticosteroids in dermatology.Update on the management of chronic eczema: new approaches and emerging treatment optionsComparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal.Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development.A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.The Economics Burden of Atopic Dermatitis.Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk infants not exclusively breastfed in Singapore.Willingness to pay and quality of life in patients with atopic dermatitis.
P2860
Q31043661-FF6DD523-796D-454A-8212-1E0121CD3E45Q35555611-3EC255B6-AB03-45C7-BBD0-658ED37369DDQ36648569-A85912CD-602B-4C2E-8029-34F6BA9C0498Q36835052-9D86B624-61B1-4147-89BA-7E748776814DQ36835056-2A983B3D-5907-461C-B1AC-ECA7C52D0168Q36895865-1D554F75-F786-4E7C-AFD4-871004426F94Q37857682-C1816B86-B827-4990-A837-A201AFED1B52Q37977478-D023749B-8941-4B4A-9A0A-C3441CD0BB17Q38597139-05E0DEC0-0422-4F16-A510-0DC0B1847045Q38956660-0BBDB913-A041-47E0-A585-66EC38845037Q40068394-919BC6A2-51CB-4732-9BF5-AC6C02C56462Q42633680-8F98ADCB-176B-4E99-B9AA-BB46EEC52F2EQ47235881-E6BE5A7A-26AB-447E-928E-A5354DB6D084Q47353933-8383545B-CCC2-4AA1-A9FF-C0FBA5BE1166Q48158729-40477156-F24E-42D7-8EC3-49CAFCF2D2D9
P2860
A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
A cost-utility analysis of pim ...... ld and moderate atopic eczema.
@ast
A cost-utility analysis of pim ...... ld and moderate atopic eczema.
@en
type
label
A cost-utility analysis of pim ...... ld and moderate atopic eczema.
@ast
A cost-utility analysis of pim ...... ld and moderate atopic eczema.
@en
prefLabel
A cost-utility analysis of pim ...... ld and moderate atopic eczema.
@ast
A cost-utility analysis of pim ...... ld and moderate atopic eczema.
@en
P2860
P1476
A cost-utility analysis of pim ...... ild and moderate atopic eczema
@en
P2860
P304
P356
10.1111/J.1365-2133.2006.07184.X
P407
P50
P577
2006-06-01T00:00:00Z